BSE Live
Apr 15, 16:01Prev. Close
344.95
Open Price
348.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 15, 15:59Prev. Close
345.00
Open Price
347.90
Bid Price (Qty.)
350.35 (623)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Biocon (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 609.30 | 119.30 | 2,848.40 | 86.10 | 280.50 | |
| Net CashFlow From Operating Activities | 623.90 | -123.20 | 219.30 | 47.60 | 478.40 | |
| Net Cash Used In Investing Activities | -991.80 | -296.40 | -1,177.80 | -305.60 | -618.30 | |
| Net Cash Used From Financing Activities | 494.80 | 343.60 | 1,039.40 | 112.00 | 27.80 | |
| Foreign Exchange Gains / Losses | 0.30 | 1.70 | 4.70 | 3.50 | -9.40 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 127.20 | -74.30 | 85.60 | -142.50 | -121.50 | |
| Cash And Cash Equivalents Begin of Year | 122.30 | 196.60 | 111.00 | 253.50 | 375.00 | |
| Cash And Cash Equivalents End Of Year | 249.50 | 122.30 | 196.60 | 111.00 | 253.50 |
08.04.2026
31.03.2026
11.03.2026
17.02.2026
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth